Target intelligence / Profile preview

Gut microbiota and host intestinal mucosa

Molecular classification
Other (Biological System), Microbiome-host interface
01

Overview

The gut microbiota and host intestinal mucosa constitute a dynamic ecosystem and physical barrier essential for maintaining systemic homeostasis. The microbiota, comprising bacteria, fungi, and viruses, performs critical metabolic functions such as the fermentation of non-digestible carbohydrates into short-chain fatty acids, which serve as energy for colonocytes (Nature Reviews Microbiology, 2016). The host mucosa acts as a selective barrier, utilizing a mucus layer, antimicrobial peptides, and a tight junction-linked epithelial layer to prevent the translocation of pathogens while allowing nutrient absorption (Science, 2017). Disruptions in this interface, known as dysbiosis or "leaky gut," are central to the pathogenesis of inflammatory bowel diseases, metabolic disorders, and certain cancers (Cell, 2020). Pharmacological and biotherapeutic interventions target this system by introducing beneficial microbes, providing prebiotic substrates, or using biologics to stabilize the host immune response at the mucosal surface.

Other names
Gut-microbiome-host interfaceIntestinal mucosal barrierGut-microbiota-mucosal axisIntestinal microbiota-host interface
02

Mechanism of action

Therapeutic strategies involve the modulation of microbial populations to reduce pro-inflammatory signals, the reinforcement of the intestinal epithelial barrier, and the induction of regulatory T-cell responses through microbial metabolites like short-chain fatty acids (SCFAs).

03

Biological functions

Immune system modulationMetabolic homeostasisBarrier functionPathogen exclusionNutrient absorption
04

Disease associations

Inflammatory bowel diseaseIrritable bowel syndromeMetabolic syndromeColorectal cancerObesityCeliac disease
05

Safety considerations

Risk of systemic translocation of bacteria (bacteremia)Induction of dysbiosisTransfer of antibiotic resistance genesVariability in host response to microbial modulationPotential for opportunistic infections in immunocompromised patients
06

Interacting drugs

Rifaximin

5 more in the full profile.

07

Biomarkers

Fecal calprotectinZonulinMicrobial alpha-diversityShort-chain fatty acid (SCFA) levelsIntestinal fatty acid-binding protein (I-FABP)

Beyond the preview

Go deeper on Gut microbiota and host intestinal mucosa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gut microbiota and host intestinal mucosa.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call